S&P 500   4,585.89 (+1.17%)
DOW   35,367.73 (+0.97%)
QQQ   372.32 (+1.59%)
AAPL   169.05 (+1.70%)
MSFT   310.24 (+2.28%)
FB   324.25 (+1.46%)
GOOGL   2,738.56 (+1.34%)
AMZN   3,127.49 (+0.05%)
TSLA   1,033.11 (+3.76%)
NVDA   253.93 (+1.30%)
BABA   133.48 (+4.49%)
NIO   30.40 (+6.18%)
AMD   127.87 (-0.31%)
CGC   7.97 (+4.32%)
MU   89.46 (-0.60%)
GE   101.12 (+0.50%)
T   27.34 (+0.22%)
F   22.28 (-0.76%)
DIS   151.30 (+0.79%)
AMC   19.10 (+4.26%)
PFE   54.16 (+1.16%)
ACB   5.00 (+2.88%)
BA   220.02 (+1.35%)
S&P 500   4,585.89 (+1.17%)
DOW   35,367.73 (+0.97%)
QQQ   372.32 (+1.59%)
AAPL   169.05 (+1.70%)
MSFT   310.24 (+2.28%)
FB   324.25 (+1.46%)
GOOGL   2,738.56 (+1.34%)
AMZN   3,127.49 (+0.05%)
TSLA   1,033.11 (+3.76%)
NVDA   253.93 (+1.30%)
BABA   133.48 (+4.49%)
NIO   30.40 (+6.18%)
AMD   127.87 (-0.31%)
CGC   7.97 (+4.32%)
MU   89.46 (-0.60%)
GE   101.12 (+0.50%)
T   27.34 (+0.22%)
F   22.28 (-0.76%)
DIS   151.30 (+0.79%)
AMC   19.10 (+4.26%)
PFE   54.16 (+1.16%)
ACB   5.00 (+2.88%)
BA   220.02 (+1.35%)
S&P 500   4,585.89 (+1.17%)
DOW   35,367.73 (+0.97%)
QQQ   372.32 (+1.59%)
AAPL   169.05 (+1.70%)
MSFT   310.24 (+2.28%)
FB   324.25 (+1.46%)
GOOGL   2,738.56 (+1.34%)
AMZN   3,127.49 (+0.05%)
TSLA   1,033.11 (+3.76%)
NVDA   253.93 (+1.30%)
BABA   133.48 (+4.49%)
NIO   30.40 (+6.18%)
AMD   127.87 (-0.31%)
CGC   7.97 (+4.32%)
MU   89.46 (-0.60%)
GE   101.12 (+0.50%)
T   27.34 (+0.22%)
F   22.28 (-0.76%)
DIS   151.30 (+0.79%)
AMC   19.10 (+4.26%)
PFE   54.16 (+1.16%)
ACB   5.00 (+2.88%)
BA   220.02 (+1.35%)
S&P 500   4,585.89 (+1.17%)
DOW   35,367.73 (+0.97%)
QQQ   372.32 (+1.59%)
AAPL   169.05 (+1.70%)
MSFT   310.24 (+2.28%)
FB   324.25 (+1.46%)
GOOGL   2,738.56 (+1.34%)
AMZN   3,127.49 (+0.05%)
TSLA   1,033.11 (+3.76%)
NVDA   253.93 (+1.30%)
BABA   133.48 (+4.49%)
NIO   30.40 (+6.18%)
AMD   127.87 (-0.31%)
CGC   7.97 (+4.32%)
MU   89.46 (-0.60%)
GE   101.12 (+0.50%)
T   27.34 (+0.22%)
F   22.28 (-0.76%)
DIS   151.30 (+0.79%)
AMC   19.10 (+4.26%)
PFE   54.16 (+1.16%)
ACB   5.00 (+2.88%)
BA   220.02 (+1.35%)
OTCMKTS:XYNO

Xynomic Pharmaceuticals Stock Forecast, Price & News

$2.22
0.00 (0.00%)
(As of 06/23/2021)
Add
Compare
Today's Range
$2.22
$2.22
50-Day Range
$2.22
$2.22
52-Week Range
$0.20
$3.84
Volume
N/A
Average Volume
875 shs
Market Capitalization
$102.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-1.55
30 days | 90 days | 365 days | Advanced Chart
Receive XYNO News and Ratings via Email

Sign-up to receive the latest news and ratings for Xynomic Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


About Xynomic Pharmaceuticals

Xynomic Pharmaceuticals Holdings, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drug candidates for the treatment of cancer in the People's Republic of China and the United states. Its lead drug candidate is Abexinostat, an orally dosed hydroxamic acid-based small molecule histone deacetylase inhibitor. The company develops pazopanib a molecular therapy for treating renal cell carcinoma; XYN-603 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory (R/R) mantle cell lymphoma or R/R diffuse large b-cell lymphoma (DLBCL); and XYN-604, which is in phase 1b trial for treatment of multiple solid tumors. It also develops single agent monotherapy products that is in phase II clinical trial, including XYN-601 for treatment of R/R follicular lymphoma (FL); XYN-606 to treat R/R DLBCL; and XYN-605 for treatment of R/R FL. In addition, the company develops drug candidate XP-105, a mTORC1/2 inhibitor, which has completed Phase I clinical trial for treatment of breast cancer. Further, its pre-clinical oncology drug candidate include XP-102 (BI 882370), a pan-RAF inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:XYNO
CIK
N/A
Fax
N/A
Employees
27
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
6,344,000
Market Cap
$102.73 million
Optionable
Not Optionable

Company Calendar

Today
1/20/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

0.33 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Xynomic Pharmaceuticals (OTCMKTS:XYNO) Frequently Asked Questions

Who are Xynomic Pharmaceuticals' key executives?

Xynomic Pharmaceuticals' management team includes the following people:
  • Mr. Yinglin Xu, Co-Founder, Pres, Chairman & CEO (Age 50)
  • Ms. Jinwei Kou, CFO & Chief Accounting Officer (Age 39, Pay $62.69k)
  • Dr. Wentao Wu Ph.D., Chief Operating Officer (Age 54, Pay $160.01k)
  • Dr. Sophia Paspal Ph.D., Chief Devel. Officer (Age 50, Pay $252.55k)
  • Mr. Tingzhi Qian, Exec. Director (Age 42)
  • Dr. James Jiayuan Tong M.D., Ph.D., Chief Strategy Officer, Exec. VP & Exec. Director (Age 48)

What is Xynomic Pharmaceuticals' stock symbol?

Xynomic Pharmaceuticals trades on the OTCMKTS under the ticker symbol "XYNO."

How do I buy shares of Xynomic Pharmaceuticals?

Shares of XYNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xynomic Pharmaceuticals' stock price today?

One share of XYNO stock can currently be purchased for approximately $2.22.

How much money does Xynomic Pharmaceuticals make?

Xynomic Pharmaceuticals has a market capitalization of $102.73 million.

How many employees does Xynomic Pharmaceuticals have?

Xynomic Pharmaceuticals employs 27 workers across the globe.

What is Xynomic Pharmaceuticals' official website?

The official website for Xynomic Pharmaceuticals is xynomicpharma.com.

Where are Xynomic Pharmaceuticals' headquarters?

Xynomic Pharmaceuticals is headquartered at K. WAH CENTRE 1010 MIDDLE SUITE 3306 HUAIHAI ROAD, BEIJING F4, 200031.

How can I contact Xynomic Pharmaceuticals?

Xynomic Pharmaceuticals' mailing address is K. WAH CENTRE 1010 MIDDLE SUITE 3306 HUAIHAI ROAD, BEIJING F4, 200031. The company can be reached via phone at 86 21 5418 0212 or via email at [email protected].


This page was last updated on 1/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.